5PSQ-023 Neutropenia as an indicator of trifluridine-tipiracil efficacy in metastasic colorectal cancer

Background and importanceTrifluridine-tipiracil (TAS102) is indicated in third- and/or fourth-line metastasic colorectal cancer (mCRC) after progression with standard treatments based on overall survival benefit shown in the RECOURSE and J003 studies. Longer survival is shown in patients who develop neutropenia as a toxicity.Aim and objectivesAnalysis of correlation between efficacy of TAS102 and neutropenia.Material and methods43 patients with mCRC treated with this drug between January 2018 and September 2021 at Juan Ramón Jiménez Hospital (Huelva). Variables described: age, sex, KRAS mutation, performance status (PS), line of treatment and toxicities. Relationship between overal survival (OS) and progression-free survival (PFS) and the grade of neutropenia analysed by means of a Cox regression analysis, obtaining a hazard ratio. Survival medians presented using Kaplan–Meier curves.ResultsMedian age, 66 years. 58.3% were men. Only 6 patients with PS >2. 97.5% had neutropenia (51.3% grade 1, 41% grade 2 and 7.7% grade 3). All patients progressed, 79.1% have died to date.The regression analysis was statistically significant (p=0.05); the variables grade of neutropenia and G3 neutropenia (neutrophils